文献速递浆细胞疾病

p53蛋白亚型的表达可预测多发性骨髓瘤患者的生存

Expression of p53 protein isoforms predicts survival in patients with multiple myeloma.
PubMed 文献 · Am J Hematol · 2022-03-01

研究采用毛细管纳米免疫分析法,在156例新诊断多发性骨髓瘤患者中定量检测p53蛋白亚型表达,并分析其预后价值。结果显示,TAp53β/γ高表达(HR 4.49)和高危细胞遗传学(HR 2.69)为独立预后因素;将p53亚型表达纳入细胞遗传学风险分类可显著改善风险分层。

要点

  • TAp53β/γ高表达与较短至进展时间独立相关(HR 4.49)。
  • 高危细胞遗传学与较短至进展时间独立相关(HR 2.69)。
  • 纳入p53亚型表达可改善现有细胞遗传学风险分类。

核心结论

  • p53蛋白亚型表达在多发性骨髓瘤中具有预后价值,TAp53β/γ高表达与短生存相关,短亚型低表达与不良预后相关,纳入p53亚型表达可改善细胞遗传学风险分层。

研究设计与样本

  • 研究纳入156例新诊断多发性骨髓瘤患者,均为PETHEMA/GEM2012临床试验治疗人群,采用毛细管纳米免疫分析法在CD138纯化样本中定量p53蛋白亚型表达,并用实时定量PCR在RNA水平验证。

主要发现

  • 短p53亚型低表达和TAp53β/γ亚型高表达与多发性骨髓瘤患者不良预后相关。
  • 多因素Cox模型显示,TAp53β/γ高表达(HR 4.49,p < .001)和高危细胞遗传学(HR 2.69,p < .001)为与较短至进展时间相关的独立预后因素。
  • 将p53蛋白亚型表达水平纳入现有细胞遗传学风险分类后,风险分层显著改善,高危多发性骨髓瘤中短亚型高表达者生存显著长于短亚型低表达的高危患者。

关键数值与推荐

  • TAp53β/γ高表达:HR 4.49,p < .001,与较短至进展时间独立相关。
  • 高危细胞遗传学:HR 2.69,p < .001,与较短至进展时间独立相关。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Loss and/or mutation of the TP53 gene are associated with short survival in multiple myeloma, but the p53 landscape goes far beyond. At least 12 p53 protein isoforms have been identified as a result of a combination of alternative splicing, alternative promoters and/or alternative transcription site starts, which are grouped as α, β, γ, from transactivation domain (TA), long, and short isoforms. Nowadays, there are no studies evaluating the expression of p53 isoforms and its clinical relevance in multiple myeloma (MM). We used capillary nanoimmunoassay to quantify the expression of p53 protein isoforms in CD138-purified samples from 156 patients with newly diagnosed MM who were treated as part of the PETHEMA/GEM2012 clinical trial and investigated their prognostic impact. Quantitative real-time polymerase chain reaction was used to corroborate the results at RNA levels. Low and high levels of expression of short and TAp53β/γ isoforms, respectively, were associated with adverse prognosis in MM patients. Multivariate Cox models identified high levels of TAp53β/γ (hazard ratio [HR], 4.49; p < .001) and high-risk cytogenetics (HR, 2.69; p < .001) as independent prognostic factors associated with shorter time to progression. The current cytogenetic-risk classification was notably improved when expression levels of p53 protein isoforms were incorporated, whereby high-risk MM expressing high levels of short isoforms had significantly longer survival than high-risk patients with low levels of these isoforms. This is the first study that demonstrates the prognostic value of p53 isoforms in MM patients, providing new insights on the role of p53 protein dysregulation in MM biology.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Rojas EA, Corchete LA, De Ramón C, et al. Expression of p53 protein isoforms predicts survival in patients with multiple myeloma. Am J Hematol. 2022. PMID: 35188691. doi:10.1002/ajh.26507

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。